Richard Klausner, Director at Juno Therapeutics, Inc. (JUNO), sold 24,530 shares at $46.85 ($1.2M) on 2018-01-08, disclosed to the SEC on 2018-01-09.
Open-market sale of $1.2M JUNO by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $46.85 | 1,949 | $91K | 7.7% |
| 2 | $46.85 | 1,949 | $91K | 7.7% |
| 3 | $47.80 | 5,011 | $240K | 20.3% |
| 4 | $47.80 | 5,011 | $240K | 20.3% |
| 5 | $48.95 | 4,846 | $237K | 20.1% |
| 6 | $48.95 | 4,846 |
| $237K |
| 20.1% |
| 7 | $49.37 | 918 | $45K | 3.8% |
| Total | $48.16 avg | 24,530 | $1.2M | 100% |
| Filing → |
| LYEL | SELL | 2022-09-27 | $71K | — | Filing → |
| JUNO | SELL | 2017-12-22 | $3.2M | — | Filing → |
| JUNO | SELL | 2017-09-08 | $1.0M | — | Filing → |